Radiation-Immuno combo aims to boost HPV throat cancer response before surgery
NCT ID NCT05787639
First seen May 25, 2026 · Last updated May 25, 2026
Summary
This study tests whether giving targeted radiation along with two immunotherapy drugs (evorpacept and pembrolizumab) before standard surgery can improve outcomes for people with early-stage HPV-related throat cancer. About 29 adults with stage I disease that can be surgically removed will receive this combination treatment. The main goal is to see if the cancer disappears or shrinks significantly by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNX CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Providence Health & Services
Portland, Oregon, 97213, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.